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Summary We studied outcomes of mammographic screening in women older than 65 years. In 1975, breast
cancer screening was started in Nijmegen, The Netherlands, for women aged 35-65 years. Since 1977,
approximately 7700 older women have also been invited for biennial one-view mammography. This report is
based on ten screening rounds from 1975 to 1994. The results of the subsequent screening rounds in the age
groups 65-69 years, 70-74 years and 75 years and older were: participation rates 55%, 39% and 15%; screen-
detected cancer rates 5.6%o, 6.9%o and 7.8%o; interval cancer rates 2.0%oo, 1.8%o and 3.5%o; and predictive values
of referral 62%, 64% and 62% respectively. In all age groups, screen-detected patients had smaller tumours
and a lower prevalence ofaxillary lymph node involvement than unscreened patients. Our conclusion is that, in
women aged 65 years and older, breast cancer can be detected at an earlier stage by mammographic screening.
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Breast cancer is the commonest malignancy in women. The
incidence of invasive breast cancer in The Netherlands rises
with age to about 340 new diagnosis annually per 100 000
women aged 70 years and older (Netherlands Cancer
Registry, 1995). Approximately one out of three new cases
of invasive breast cancer is diagnosed in this age group.
Although it has often been argued that this disease is more
indolent in older women, their relative survival is no better
than for younger women (Yancik et al., 1989).
Several trials have been conducted, and reviews of the
results show that mammographic screening can reduce breast
cancer mortality by approximately 30% (Fletcher et al., 1993;
Nystr6m et al., 1993; De Koning et al., 1995a). Recently, it
was shown that mammographic screening of women aged
65-74 years can also reduce breast cancer mortality (Van
Dijck et al., 1994, 1996; Chen et al., 1995).
To evaluate screening programmes that may have
differently aged target populations, background material is
necessary in order to assess the early results. For women aged
50-69 years, this information is available from several
regional and national programmes (Peer et al., 1994; Tabar
et al., 1993; De Koning et al., 1995b; Chamberlain et al.,
1993), but for older age groups, information is limited.
The aim of the present study was to determine age-specific
outcomes of mammographic screening, with emphasis on
women aged 65 years and older, in the Nijmegen programme,
which is the only long-running trial in the world that
included women over 75 years of age (Otten et al., 1996).
Study population and methods
In 1975, a population-based screening programme for breast
cancer was started in Nijmegen, The Netherlands. In 1975
and 1976, approximately 30 000 women aged 35-65 years
received their first invitation to participate in the mass
mammographic screening. From the second round onwards,
some 7700 older women were also invited for biennial one-
view mammography. From 1975 up to 1994, ten screening
rounds were carried out. Details of the programme and the
round-specific results up to round 9 will be published
elsewhere (Otten et al., 1996).
The present analyses concerned primary breast cancer
patients diagnosed before December 1994. Excluded were
patients with lobular carcinoma in situ, patients diagnosed
before their first invitation to screening and women under the
age of 50. Age, defined as the age on the date ofinvitation, was
categorised as 50-64, 65-69, 70-74 and 75 years and older.
The following indicators were studied for first and
subsequent invitations separately: participation rate (i.e.
number of accepted invitations per 100 invitations); referral
rate (i.e. number of referrals for diagnostic work-up per 1000
accepted invitations); screen-detected cancer rate (i.e. number
of screen-detected patients per 1000 accepted invitations);
interval cancer rate (i.e. number of patients diagnosed
clinically after a negative screening result but before the
next scheduled invitation 2 years later per 1000 accepted
invitations); and the non-participant cancer rate (i.e. number
of cancers diagnosed clinically in non-participants per 1000
rejected invitations). The predictive value of referral (i.e. the
number of diagnosed breast cancer patients per 100 referred
women) and the ratio of screen-detected patients to screen-
detected plus interval cancer patients were also calculated.
Tumour size and lymph node status were studied according
to the detection mode: (1) detected at first screening
(including screen-detected patients who had rejected the
invitation 2 years earlier); (2) detected at repeated screening
(i.e. in women who had also participated in the previous
round); (3) diagnosed clinically as an interval cancer; and (4)
diagnosed clinically in non-participants (i.e. in women who
had rejected the most recent invitation). Tumour size was
measured in millimetres (mm) as the largest mneasurable size
on the mammogram, or on the specimen radiography and
histological slides if the tumour had vague margins or was
radiographically occult. Axillary lymph node status was
studied in patients diagnosed after 31 December 1980.
Before this date, axillary lymph node dissection was not
performed as a routine procedure and, as a result, the lymph
node status was missing in 34% of the patients. From 1981
onwards, the axillary lymph node status was missing in 10%
of the patients.
The statistical tests used were the Kruskal Wallis test to
analyse differences in median tumour size and the chi-square
test for contingency tables to test differences in proportions.
The analyses were performed with the statistical software
package SAS.
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Table I shows the number ofinvitations and the participation
rates, referral rates and cancer rates for the first invitation.
The participation rates for the first invitation decreased
dramatically at older ages from 81% in women aged 50 -64
years to 24% in women aged 75 years and older, while those
for the subsequent invitations were some 10% lower at all
ages. Table II shows corresponding details for subsequent
invitations. The initial high rates of referral and detection
(18% and 9%) dropped in the subsequent invitations to levels
of about 10 and 6 per 1000 accepted invitations in women
aged 65 years and older. The breast cancer detection rates in
women who had been screened regularly (i.e. those also
screened in the previous round) remained fairly high at 3.0,
5.5, 6.0 and 6.3 per 1000 accepted invitations for the four age
groups (not included in the tables). Interval cancer rates were
slightly higher after subsequent invitations than after the first
invitation. The non-participant cancer rates did not increase
in the older age groups. The predictive value of referral was
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very high. At subsequent invitations, breast cancer was
diagnosed in two out of three referred women aged 65 and
older. The ratio of screen-detected cancers to the sum of
screen-detected plus interval cancers was 0.69 or higher in
women older than age 65.
Table III shows the tumour size of invasive cancers,
categorised as < 10 mm, 11 -20 mm and >20 mm, according
to the detection mode and age. The median tumour sizes
(with 25th and 75th centiles) are also presented. In each age
group, the median size was smallest in the cancers detected at
repeat screening and largest in non-participant cases (P-
values <0.001). The proportion of large tumours detected at
first screening or those diagnosed in non-participants was
somewhat larger in the oldest age groups (chi-square= 5.62,
d.f.=3, P=0.13; chi-square=5.82, d.f.=3, P=0.12), while
the proportion of large interval cancers was slightly smaller in
the oldest women (chi-square=5.17, d.f.=3, P=0.16).
Table IV shows the lymph node status of women
diagnosed between 1981 and 1994. Overall, the percentage
'unknown' was 5%, 6%, 5% and 30% in the four age groups
Table I First invitations: screening results according to age at invitation
Screening result
No. of invited women
No. of participants
Participation rate (%)
Referrals
No.
Ratea
Screen-detected cancers
No.
Ratea
Interval cancers
No.
Ratea
Non-participant cancers
No.
Rateb
Predictive value of
referral (%)
Ratio screen-detected
to screen-detected
plus interval
50-64
13 149
10 591
81
158
14.9
604
5.7
17'
1.6
141
5.5
38
0.78
Age at invitation (years)
65-69 70-74
2328
1440
62
22
15.3
81
5.6
2'
1.4
3
3.4
36
0.80
3122
1450
46
27
18.6
152
10.3
3
2.1
S
3.0
56
0.83
75 +
4253
1009
24
20
19.8
13'
12.9
2
2.0
13
4.0
65
0.87
Total
22 852
14 490
63
227
15.7
968
6.6
242
1.7
351
4.2
42
0.80
b
Superscript denotes number of ductal carcinoma in situ included. a Per 1000 accepted invitations. Per 1000
rejected invitations.
Table II Subsequent invitations: screening results according to age at invitation
Age at invitation (years)
Screening result 50-64 65-69 70- 74 75+ Total
No. of invitations 98 851 28 398 21 079 33 949 182 277
No. of participations 66 073 15 708 8116 5129 95 026
Participation rate (%) 67 55 39 15 52
Referrals
No. 401 143 87 65 696
Ratea 6.1 9.1 10.7 12.7 7.3
Screen-detected cancers
No. 2204' 888 566 405 4046°
Ratea 3.3 5.6 6.9 7.8 4.3
Interval cancers
No. 1326 322 15 18' 1979
Ratea 2.0 2.0 1.8 3.5 2.1
Non-participant cancers
No. 1073 512 492 1223 32910
Rateb 3.3 4.0 3.8 4.2 3.8
Predictive value of 55 62 64 62 58
referral (%)
Ratio screen-detected 0.63 0.73 0.79 0.69 0.67
to screen-detected
plus interval
Superscript denotes number ofductal carcinoma in situ included. aPer 1000 accepted invitations. bPer 1000
rejected invitations.Mammographic screening outcomes in elderly women
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(chi-square=92.4, d.f.=3, P<0.001). Breast cancer-specific
survival was poorest in patients with an unknown lymph
node status; the 10 year breast cancer-specific survival rate
was 0.40 for patients with unknown lymph node status,
whereas it was 0.61 for patients with positive nodes and 0.92
for patients with negative nodes. This illustrates the
importance of considering all diagnosed patients instead of
only those with a known lymph node status as the
denominator for the proportion of patients with negative
nodes. The proportion of lymph node-negative patients
differed according to the detection mode (chi-square=65.8,
d.f.=3, P<0.001). In the patients detected at repeat
screening it was 74%, while in non-participants it was 41%.
In non-participants aged 75 years and older, the proportion
of lymph node negatives was smaller than in the younger
non-participants (34% and 47% respectively, P=0.03).
Discussion
Mammographic screening can obviously only reduce the
mortality of breast cancer in the population if at least a
proportion of the invitees participates. The participation rates
in women for the first invitation (65-69 years, 81%; 70-74
years, 67% and 51% for older women), declined for
subsequent invitations (64% for ages 50-69, 39% for ages
Table III Tumour size of invasive cancers according to detection mode and age at invitation
Detection mode and Age at invitation (years)
tumour size 50-64 65-69 70-74 75+ Total
Detected at first screeninga
10mm 25 (28) 5 (29) 4 (16) 5 (21) 39 (25)
11-20mm 46 (51) 10 (59) 16 (64) 9 (38) 81 (52)
>20mm 19 (21) 2 (12) 5 (20) 10 (41) 36 (23)
Total 90 17 25 24 156
Median (25 -75 centile) 15 (10-20) 15 (10-15) 20 (15-20) 20 (14-27) 15 (11-20)
Detected at repeat screening
10mm 57 (39) 27 (38) 14 (38) 11 (48) 109 (40)
10 -20mm 66 (46) 35 (49) 21 (55) 7 (30) 129 (47)
>20mm 22 (13) 9 (13) 2 (6) 5 (22) 39 (14)
Total 145 71' 371 23 2762
Median (25 -75 centile) 15 (10-18) 15 (10-20) 15 (10-18) 12 (7-20) 15 (10-20)
Diagnosed as interval cancer
10mm 19 (14) 3 (10) 4 (24) 4 (24) 30 (15)
10 -20mm 65 (46) 14 (45) 11 (65) 8 (47) 98 (48)
>20mm 56 (40) 14 (45) 2 (12) 5 (29) 77 (38)
Total 1402 31 17' 172 2055
Median (25 -75 centile) 20 (15-30) 20 (15-30) 15 (15-20) 20 (13 -25) 20 (15-30)
Diagnosed in non-participants
,lomm 12 (11) 4 (8) 2 (4) 5 (4) 23 (7)
11-20mm 30 (28) 13 (27) 18 (35) 27 (23) 88 (27)
>20mm 66 (61) 32 (65) 31 (61) 88 (73) 217 (66)
Total 1089 491 511 120' 3282
Median (25 -75 centile) 25 (19-35) 26 (20-35) 25 (15-35) 30 (20-40) 30 (20-35)
Percentage between parenthesis. Superscript indicates the number of missing values. aIncludes screen-detected patients who had rejected the
previous screen invitation.
Table IV Axillary lymph node status of women diagnosed after 1980 according to detection mode and age at most recent
invitation
Detection mode and Age at invitation (years)
lymph nodesa 50-64 65-69 70-74 75+ Total
Detected at first screeninga
Negativeb 22 (61) 7 (70) 13 (76) 6 (55) 48 (65)
Positive 13 (36) 3 (30) 3 (18) 3 (27) 22 (30)
Not examined 1 (3) 0 (0) 1 (6) 2 (18) 4 (5)
Total 36 10 17 11 74
Detected at repeat screening
Negativeb 107 (78) 44 (69) 30 (77) 14 (64) 195 (74)
Positive 27 (20) 19 (30) 9 (23) 4 (18) 59 (23)
Not examined 3 (2) 1 (2) 0 (0) 4 (18) 8 (3)
Total 137 64 39 22 262
Diagnosed as interval cancer
Negativeb 69 (63) 19 (66) 7 (50) 12 (67) 107 (63)
Positive 34 (31) 10 (34) 3 (21) 4 (22) 51 (30)
Not examined 6 (6) 0 (0) 4 (29) 2 (11) 12 (7)
Total 109 29 14 17 170
Diagnosed in non-participants
Negativeb 44 (46) 20 (48) 21 (47) 41 (34) 126 (42)
Positive 45 (47) 15 (36) 23 (51) 36 (30) 119 (39)
Not examined 7 (7) 7 (17) 1 (2) 43 (36) 58 (19)
Total 96 42 45 120 303
a Includes screen-detected patients who had rejected the previous screen invitation. bWomen with DCIS included as negative.Mammographic screening outcomes in elderly women
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70-74, and 15% for older women). These rates were
disappointing compared with the two-county trial in
Sweden, in which, among women aged 70-74 years, 72%
participated after subsequent invitations (Arnesson et al.,
1995).
The effect of screening in the women who actually do
participate may appear fairly large because the women who
continue to participate have a longer life expectancy. In
another study, we found a marked difference in survival of
women who continued to participate at the age of 65-66
years compared with those who discontinued. The 10 year
cumulative survival rates were 0.87 and 0.73 respectively (Van
Dijck et al., 1996). In Stockholm, similar results were
reported in participants and non-participants aged 40-64
years (Lidbrink et al., 1995). It is possible that participants
had fewer co-existing diseases or that these were less severe.
There may even be an interaction between breast cancer and
certain co-existing diseases. In breast cancer patients with
localised or regional disease, Satariano and Ragland (1994)
found that the probability of survival decreased with an
increasing number of co-existing conditions, whereas in
patients with distant metastases, the 3 year survival rate did
not depend on the number of other conditions. They
concluded that women with severe co-existing diseases would
not have a survival advantage because of early diagnosis.
One of the reasons for participation may be awareness of
the presence of risk factors for breast cancer. If this is true,
non-participants will be at less risk of breast cancer. The
finding that the non-participant cancer rates did not increase
with increasing age, in contrast to the screen-detected cancer
rates and interval cancer rates, supports this hypothesis. In
women over the age of 65, these non-participant cancer rates
were approximately 2 per 1000 rejected invitations per
annum, whereas the annual incidence of breast cancer in
The Netherlands is about 3.5 per 1000 women (Netherlands
Cancer Registry, 1995). In an earlier study, we also observed
that the incidence of breast cancer in the non-participants
was lower than would have been expected on the basis of a
population without mass screening (Van Dijck et al., 1996).
This means that one explanation for the high incidence in
elderly participants, which was 4.5 per 1000 accepted
subsequent invitations per annum at ages 65+ (calculated
by the summation of screen-detected cancer and interval
cancer rates in Table II), may be that the women who
participate at a more advanced age are at greater risk for
breast cancer. However, part of the increased incidence in
participants may be artificial, because some of the detected
cancers may never have become clinically detectable.
As breast cancer incidence increases with increasing age, it
was expected that screen-detected cancer rates and interval
cancer rates would also show the same pattern. Owing to the
slower growth rate (Peer et al., 1993), it was expected that the
ratio of screen-detected to screen-detected plus interval
cancers would increase with increasing age. In the 75+
group, however, the proportion of interval cancers was
relatively high. In order to find an explanation for this result,
we reviewed the previous screening mammograms of 17 out
of the 18 interval cancers. Two tumours (12%) had been
missed at the previous screening examination; five tumours
(29%) were visible in retrospect, but the signs were not
specific enough for referral; and ten tumours (59%) had been
radiographically occult at the previous screening. These
findings are in agreement with the results of our study in
1993 and do not provide an explanation for the high interval
cancer rate (Van Dijck et al., 1993).
Two indicators of stage, i.e. tumour size and lymph node
status, were studied. In all age groups, screen-detected
tumours were the smallest. Tumours detected at repeat
screening had a median size of roughly 15 mm, whereas in
non-participants the median size was 25-30 mm. In all age
groups there was a similar increase in the proportion of
patients with negative axillary nodes due to detection at
repeat screening vs clinical detection in non-participants.
Thus, it may be concluded that, through periodic screening
with mammography in women over the age of 65, breast
cancer can be detected at a similar early stage as in those
aged 50-64 years.
In summary, our data show that, in women aged 65 years
and older, breast cancer can be diagnosed at an earlier stage
by mammographic screening. This does not imply that the
life expectancy of all screen-detected patients will be longer.
First, a larger proportion of the screen-detected cancers may
have remained undiagnosed without screening because of the
slow growth rate (Peer et al., 1993). Second, women of 75
have a life expectancy of 11 years and those of 85 of 6 years
(Wegman, 1993). The duration of the detectable preclinical
phase in women aged 70 years and older has been estimated
at 4.5 years (Peer et al., 1996). It is thus unlikely that many
breast cancer deaths can be prevented in patients screened at
age 75 years and older, but the quality of life may be
increased if screening can prevent them from having to live
for years with metastases.
We conclude that there is reason to continue mammo-
graphic screening until at least the age of 75 years. The
beneficial effects of mammographic screening on breast
cancer mortality and the quality of life may outweigh the
negative side-effects until the age when life expectancy is
shorter than the detectable preclinical phase of the disease.
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